Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Larrar, S
Right arrow Articles by Bader-Meunier, B
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Larrar, S
Right arrow Articles by Bader-Meunier, B
Haematologica, Vol 91, Issue 8_Suppl, ECR36-ECR36
Copyright © 2006 by Ferrata Storti Foundation

Case Reports

Severe hematological side effects following Rituximab therapy in children

S Larrar, C Guitton, M Willems, and B Bader-Meunier

Department of pediatrics, Bicetre hospital, 94 270 Le Kremlin Bicetre, France.

Rituximab use in severe auto-immune diseases has recently increased. Scattered reports of opportunistic infections were the only reported serious side effects related to rituximab in pediatric patients .Here, we report transient severe acute thrombocytopenia and neutropenia respectively a few days after rituximab infusion in two children with autoimmune haemolytic anaemia. In both cases, cytopenia was reversible in a few days. The occurrence of cytopenias shortly after an infusion and their rapid reversibility suggest that these hematological side-effects were attributable to a direct toxicity of rituximab. Blood cell count must be carefully monitored after rituximab infusion in young children with autoimmune diseases.




HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.